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Abstract: Granulomatosis with polyangiitis (GPA, formerly Wegener’s granulomatosis) is a 
multisystem autoimmune condition associated with anti-neutrophil cytoplasm antibodies. Man-
agement of GPA can be complex, owing to the sometimes fulminant and multisystem nature of 
the presentation, the age demographics of the affected population, and a significant incidence of 
disease relapse. In this paper, we discuss how some of the challenges in the management of GPA 
have been and continue to be addressed including: reducing the toxicity of induction therapy; 
developing biomarkers to determine who can safely stop maintenance immunosuppression; 
improving the efficacy of maintenance therapy for relapsing patients; managing localized dis-
ease; and management of disease and treatment-associated comorbidity. Consideration is also 
given to emerging therapeutics in the treatment of GPA.
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Introduction
Granulomatosis with polyangiitis (GPA, formerly known as Wegener’s granulomatosis) 
is one of the anti-neutrophil cytoplasm antibody (ANCA)-associated small vessel vas-
culitides (AAV).1 The other clinical syndromes associated with ANCA are microscopic 
polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (formerly known 
as Churg Strauss syndrome).2 Characteristic pathological features of GPA include 
arteritis of small-sized to medium-sized blood vessels, and granulomatous inflammation 
of the upper airways and lungs.1 Renal involvement with a pauci-immune necrotizing 
glomerulonephritis is one of the commonest severe manifestations, occurring in 75% 
of patients during the course of the disease,3,4 and AAV is the commonest cause of a 
pulmonary-renal syndrome presenting with acute renal dysfunction and pulmonary 
hemorrhage.5 AAV are rare diseases with a combined incidence of 20 per million per 
year and a prevalence of 144 per million in the UK.6 Two thirds of cases of AAV in the 
UK are GPA.6 AAV can occur at any age, including childhood, but is most common in 
older patients (peak age 55–70 years), and occurs equally in both sexes.6 AAV causes 
significant morbidity and mortality, with end-stage renal failure occurring in more 
than 20% of patients at 5 years and a 5-year survival rate of approximately 75%.7,8 
Prompt diagnosis and treatment is important to avoid mortality and/or permanent organ 
damage. With treatment, 85%–90% of patients will go into remission,9 but the disease 
follows a relapsing-remitting course, with a 50% relapse rate within 5 years.10 This 
review focuses on challenges in the management of GPA. In order to set the context 
for this, we first give a brief overview of the pathogenesis and clinical features of GPA 
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in the context of AAV as a whole. More detailed informa-
tion on these aspects can be obtained from other recent 
reviews.11,12
Pathogenesis of AAV
ANCA are directed against glycoprotein enzymes  present 
in neutrophil granules and monocyte lysosomes, most nota-
bly proteinase 3 (PR3)13 and myeloperoxidase (MPO).14 
Cytokine-primed neutrophils and monocytes express the 
target antigens on their surface.15 Binding of ANCA to 
these antigens activates the cells, leading to a superoxide 
burst, and release of lytic enzymes and proinflammatory 
cytokines such as interleukin (IL)-8.16–18 ANCA binding to 
neutrophils promotes endothelial adhesion and cytotoxicity 
to cultured endothelial cells.18,19 There is in vivo evidence for 
the direct pathogenicity of MPO-ANCA from maternal-fetal 
transfer and from mouse and rat models.20–22 PR3 does not 
have a direct murine homolog, but immunoglobulin from 
PR3-ANCA-positive patients caused glomerulonephritis 
in a humanized mouse model.23 T cells are also important, 
because effector memory T cells are present in chronic vas-
culitic lesions in GPA24,25 and antigen-specific Th17 cells, 
and the cytokines IL-17 and IL-23 were raised in patients 
with active AAV.26 There is recent evidence of defective 
T and B cell regulation in AAV.27–30 Emerging data suggest 
that activation of the alternative pathway of complement is 
important in AAV, and may be a therapeutic target.31–33
Genetics of AAV
A genome-wide association study (GWAS) has confirmed 
that GPA and MPA are different diseases with different major 
 histocompatibility complex associations.34 In the GWAS, GPA 
was also associated with the gene for its autoantigen PR3, 
confirming the importance of this antigen in the pathogenesis 
of the  disease. The genetic associations were stronger for 
PR3-ANCA and MPO-ANCA rather than for the clinical syn-
dromes of GPA and MPA, prompting consideration of whether 
these biomarkers should be used to stratify patients.35
Clinical features of GPA
Systemic GPA often presents with symptoms of weight loss, 
fever, fatigue, arthralgia, and myalgia.3,4 GPA is character-
ized by granulomatous upper airways involvement in about 
90% of patients.3 Upper respiratory tract symptoms include 
epistaxis, sinusitis, otitis media, deafness, hoarseness, stridor, 
and proptosis due to orbital involvement. The granulomatous 
inflammation can lead to local damage, including nasal 
septal perforation, saddle nose, and tracheal stenosis.36 Lung 
involvement occurs in 85% of patients with GPA at some 
stage, and includes pulmonary nodules and cavities, pulmo-
nary infiltrates, pleural effusion, and pulmonary  fibrosis.3 
Alveolar hemorrhage occurs in approximately 20% of 
patients with active GPA.37 Renal involvement is a common 
feature of GPA, with necrotizing and crescentic glomerulone-
phritis occurring in 75% of patients at some point in their dis-
ease.3 Renal replacement therapy is required in 20%–30% of 
patients, either due to rapidly progressive glomerulonephritis, 
or to gradual loss of kidney function over time.7 Almost any 
organ in the body can be involved, but in particular vasculitic 
skin lesions, peripheral neuropathy, mononeuritis multiplex, 
granulomatous meningeal involvement, cardiac disease, and 
gut involvement are well recognized in GPA.3 Localized GPA 
refers to granulomatous vasculitis limited to the upper air-
ways, sinuses and orbits, or lungs, without systemic involve-
ment or constitutional symptoms, and occurs in about 5% of 
patients with GPA.38,39 However, as stated above, about 90% 
of patients with systemic GPA have granulomatous disease 
of the upper airways.3 Localized GPA has a high propensity 
for relapse,40 and can cause significant local damage over 
time,36 as well as treatment-associated morbidity if recurrent 
courses of induction treatment are required.
By contrast, MPA is characterized by systemic vasculitis 
without granulomatous disease. Pauci-immune glomerulo-
nephritis is very common in MPA;4 however, upper airways 
granulomata and pulmonary nodules are not a feature, and 
chronic lung damage in MPA tends to present with a more 
fibrosing, restrictive pattern.41 Pulmonary hemorrhage can 
occur in both active GPA and active MPA.37
Relapse risk in GPA
The relapse risk of GPA is approximately 50% at 5 years.10 
GPA and PR3-ANCA-positive patients are significantly more 
likely to relapse than patients with MPO-ANCA or MPA.40,42,43 
Patients with granulomatous disease of the upper airways are 
also more likely to relapse than those without this manifesta-
tion, whilst those with renal impairment had a reduced relapse 
risk.40,43 A rise in ANCA titer is not strongly predictive of 
relapse at an individual patient level, so it is important to 
monitor clinical symptoms and signs, as well as inflammatory 
markers.44 More information about predicting relapse in GPA 
is discussed in the section on management below.
Laboratory markers of GPA
PR3-ANCA has a high sensitivity and specificity for the 
diagnosis of active GPA (.90%), in the right clinical  context, 
although ANCA-negative and MPO-ANCA- positive cases 
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Table 1 evidence for immunosuppression in GPA, based on disease 
severity
Clinical  
phenotype
Immunosuppressive  
(plus corticosteroids)
Evidence
early systemic Methotrexate (minor disease 
only), or cyclophosphamide or  
rituximab, plus cotrimoxazole if 
nasal involvement
NORAM59,60 
RAve62,64 
Cotrimoxazole96,97
Generalized Cyclophosphamide or rituximab CYCAZAReM56 
CYCLOPS57,58 
RAve62,64 
RiTUXvAS63
Severe Cyclophosphamide or  
rituximab (given with 2 doses  
of cyclophosphamide in  
RiTUXvAS trial) plus plasma  
exchange
RiTUXvAS63 
MePeX69,70
Major relapse Cyclophosphamide or rituximab 
(rituximab more effective in  
RAve trial)
RAve62,64
Refractory  
disease
Rituximab 
intravenous immunoglobulin 
Infliximab 
 
Alemtuzumab 
Mycophenolate mofetil 
15-deoxyspergualin
Roll et al73 
Jayne et al74; 
Martinez et al75 
Booth et al78; 
Lamprecht et al127 
walsh et al76 
Joy et al79 
Birck et al77
Maintenance 
therapy
Azathioprine or methotrexate 
(or rituximab – currently under 
evaluation)
mycophenolate mofetil, leflunomide
CYCAZAReM56
iMPROve84
weGeNT85
German Network 
Study87
MAiNRiTSAN90 
Abbreviations: GPA, granulomatosis with polyangiitis; CYCAZAReM, Cyclophos-
phamide vs azathioprine for early remission phase of vasculitis; CYCLOPS, Randomized 
trial of daily oral versus pulse cyclophosphamide as therapy for ANCA-associated systemic 
vasculitis; MePeX, Methylprednisolone versus Plasma exchange; NORAM, Nonrenal 
wegener’s Granulomatosis Treated Alternatively with Methotrexate; RAve, Rituximab 
in ANCA-Associated vasculitis; RiTUXvAS, Rituximab versus Cyclophosphamide in 
ANCA-Associated vasculitis; ANCA, anti-neutrophil cytoplasm antibody; MAiNRiTSAN, 
Efficacy Study of Two Treatments in the Remission of Vasculitis; WEGENT, Wegener’s 
Granulomatosis-entretien/Maintenance; ANCA, anti-neutrophil cytoplasm antibody; 
iMPROve, international Mycophenolate Mofetil Protocol to Reduce Outbreaks of 
vasculitides.
do occur.45 However, 50% of patients with the clinical syndrome 
of localized GPA are ANCA-negative.38  Inflammatory markers 
such as erythrocyte sedimentation rate and C-reactive  protein 
are also usually raised in active AAV. The gold standard for 
diagnosis of AAV is the finding of small vessel vasculitis on 
biopsy. The kidney is usually the best site for diagnosis, where a 
pauci-immune necrotizing glomerulonephritis is seen. In GPA, 
granulomatous inflammation is present in the upper airways, but 
in practice this is often missed in small biopsies due to sampling 
errors, and nonspecific collections of inflammatory cells are 
often found in biopsies of the lung or upper airways.
Efficacy and side effects  
of current and historical  
management strategies
In the 1950s, the prognosis of generalized GPA was poor, with 
only about 10% survival at 2 years.46 In the 1970s, a regimen 
of cyclophosphamide and glucocorticoids was introduced 
at the National Institutes of Health, leading to remission in 
85%–90% of patients within 3–6 months, but high cumulative 
toxicity of cyclophosphamide.46  Improvements in supportive 
management, including the availability of hemodialysis for 
renal failure and ventilatory support for pulmonary hemor-
rhage have also improved the prognosis of severe vasculitis. 
However, high cumulative doses of cyclophosphamide have 
been associated with a number of short-term and long-term 
side effects, including infections, leukopenia, impaired fer-
tility, and cancer.47–51 Corticosteroids also have a number of 
well documented side effects, including weight gain, diabetes, 
osteoporosis, increased cardiovascular risk, psychological 
effects, and skin thinning. Studies have shown that there is a 
greater chance of death from infection than from uncontrolled 
disease within the first year of diagnosis of AAV.52
Aims of treatment of GPA
AAV are believed to be autoimmune diseases and are treated 
by immunosuppression. Treatment of AAV is divided into two 
phases, ie, an induction phase and a remission maintenance 
phase. The aim of induction treatment is to rapidly reduce 
inflammation to control signs and symptoms of disease and 
prevent permanent tissue damage. In the remission mainte-
nance phase, lower-dose immunosuppression is used to prevent 
relapse. Of course, these aims should be achieved with the 
minimum of toxicity. As a guide, Table 1 lists the induction and 
maintenance strategies that are  commonly in use for different 
severities of GPA, with reference to the evidence supporting 
them. Table 2 lists the short-term and long-term side effects that 
have been associated with the drugs most commonly used to 
treat GPA. In this review, we have chosen to discuss particular 
challenges in managing GPA, namely: reducing the toxicity of 
induction therapy for GPA; the development of predictive tools 
to determine who can safely stop maintenance immunosuppres-
sion; improving the efficacy of remission maintenance strate-
gies in GPA; managing localized GPA; and management of 
disease and treatment-related comorbidity. Finally, we discuss 
the possible future therapeutics in the management of AAV.
The results of randomized trials of induction therapy for 
AAV discussed below have enabled a reduction in the intensity 
and duration of induction immunosuppression for GPA, and 
evidence would suggest that this has led to improvements in out-
come over the past 30 years.53,54 Several of the trials have been 
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Table 2 Short-term side effects and long-term damage associated with treatment in GPA
Drug Short-term side effects Long-term damage (% affected at 
long-term follow-up)
Corticosteroids weight gain 
Skin thinning 
Purpura 
Striae 
Muscle weakness 
Diabetes 
insomnia 
Mood disturbance 
Psychosis 
Bacterial infection
Hypertension, 41.5%* 
Osteoporosis, 14.1%* 
Avascular necrosis, 0.7%* 
Cataract, 9.3%* 
Angina/CABG, 8.1%* 
Stroke, 3.7%* 
Muscle atrophy, 7.4%*
Cyclophosphamide Neutropenia 
Lymphopenia 
Bacterial infection 
Pneumocystis jirovecii pneumonia 
Hemorrhagic cystitis 
Teratogenicity
Gonadal failure, 4.1%* 
Bone marrow failure, 3%* 
Hypogammaglobulinemia128 
Bladder cancer (SiR 2.4)47 
Myeloid leukemia (SiR 3.2)47 
Nonmelanoma skin cancer (SiR 2.8)47
Rituximab infection 
Allergic reactions 
Reactivation of hepatitis B (check status  
before starting)
Progressive multifocal 
leukoencephalopathy (rare ,1:10,000)92 
Hypogammaglobulinemia (repeated doses 
or prior immunosuppression)128
Azathioprine (check TPMT before  
starting)
Lymphopenia 
Liver blood test abnormalities 
Rash 
infection
Associated with nonmelanoma skin 
cancer108,109
Methotrexate (avoid if eGFR ,30 mL  
per minute)
Nausea/gastrointestinal side effects 
Abnormal liver blood tests 
Macrocytosis 
Leukopenia 
infection 
Teratogenicity
Lung injury (,1%)129 
Liver injury (unusual if liver tests 
monitored and action taken if abnormal)
Mycophenolate mofetil Gastrointestinal upset 
Leukopenia 
infection 
Teratogenicity
Not clear whether risk of skin or 
lymphoproliferative malignancy increased
Note: *evidence from the european vasculitis Study Group trial data.48
Abbreviations: CABG, coronary artery bypass grafting; eGFR, estimated glomerular filtration rate; GPA, granulomatosis with polyangiitis; SIR, standardized incidence ratio; 
TPMT, thiopurine methyltransferase.
carried out by the European Vasculitis Study Group (EUVAS). 
In their trials, EUVAS decided to subgroup vasculitis according 
to severity, to give high-intensity treatment to induce remission 
and low-intensity immunosuppression to prevent relapse, to 
agree on a standard regimen by consensus, to test against cur-
rent best practice by randomized controlled trials, and to use 
standardized scoring systems for measuring outcome.
Reducing the toxicity of induction 
therapy for GPA
Induction therapy for GPA is effective for most patients, 
but the toxicity can be high, especially in elderly patients 
and those with severe renal impairment.55 The two main 
approaches to reduce toxicity have been to reduce the cyclo-
phosphamide exposure, and more recently, trials have been 
designed to reduce exposure to corticosteroids. Table 3 lists 
the randomized controlled trials of induction therapy that have 
been carried out in AAV over the past 20 years and summarizes 
their main outcomes, and Table 4 lists the induction trials cur-
rently ongoing or completed and not yet published. Most of 
these trials included patients with either GPA or MPA.
Reducing the doses of cyclophosphamide
The CYCAZAREM (Cyclophosphamide vs azathioprine for 
early remission phase of vasculitis) study established that it 
was possible to switch from cyclophosphamide to azathioprine 
once remission was attained at 3–6 months, thereby reducing 
cyclophosphamide exposure.56 The CYCLOPS (Randomized 
trial of daily oral versus pulse cyclophosphamide as therapy 
for ANCA-associated systemic vasculitis) trial showed that 
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Table 3 Completed multicenter randomized controlled studies of induction therapy in AAv
Induction  
trials
Indication Induction  
(trial)
Induction  
(control)
Maintenance Primary endpoint Brief results
NORAM59,60 Newly diagnosed GPA  
or MPA, with early  
systemic involvement
Oral Mtx + Pred  
(n=51)
Oral Cyc + Pred  
(n=49)
Oral Cyc/ 
Mtx + Pred
Remission at  
6 months
Mtx noninferior to oral Cyc. 
Later follow-up showed 
more relapses and more 
corticosteroid treatment in 
the Mtx group
CYCLOPS57,58 GPA or MPA with renal  
involvement but serum  
creatinine ,500 μmol/L
iv Cyc + Pred  
(n=76)
Oral Cyc + Pred  
(n=73)
Aza + Pred Time to remission iv Cyc non inferior to oral Cyc. 
Later results showed higher 
relapse rates with iv Cyc but 
no difference in mortality
MePeX69,70 Severe renal GPA or  
MPA with serum  
creatinine .500 μmol/L
Plex + oral Cyc +  
Pred (n=70)
Methyl Pred +  
oral Cyc + Pred  
(n=67)
Aza + Pred Dialysis  
independence at  
3 months
Renal survival better with 
Plex, but no difference in 
long-term mortality
RiTUXvAS63 Newly diagnosed GPA  
or MPA with renal  
involvement
Rtx + Pred + iv  
Cyc × 2 doses  
(n=33)
iv Cyc + Pred  
(n=11)
Pred alone or  
Aza + Pred
Sustained remission  
at 12 months and  
adverse event rates
Rtx noninferior to iv Cyc;  
no difference in adverse  
event rate
RAve62,64 New or relapsing GPA  
or MPA (excluding  
serum creatinine  
.4.0 mg/dL, or PH
Rtx + Pred  
(n=99)
Oral Cyc + Pred  
(n=98)
Nil or Aza  
without Pred
Remission without  
Pred at 6 months
Rtx noninferior to oral Cyc. 
Rtx more effective than Cyc 
in relapsing patients
Abbreviations: AAv, anti-neutrophil cytoplasm antibody-associated small vessel vasculitides; Mtx, methotrexate; Cyc, cyclophosphamide; Pred, oral prednisone or 
prednisolone; Methyl pred, methylprednisolone; iv, intravenous; Aza, azathioprine; Rtx, rituximab; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; Plex, 
plasma exchange; CYCLOPS, Randomized trial of daily oral versus pulse cyclophosphamide as therapy for ANCA-associated systemic vasculitis; MePeX, Methylprednisolone 
versus Plasma exchange; NORAM, Nonrenal wegener’s Granulomatosis Treated Alternatively with Methotrexate; RAve, Rituximab in ANCA-Associated vasculitis; 
RiTUXvAS, Rituximab versus Cyclophosphamide in ANCA-Associated vasculitis; ANCA, anti-neutrophil cytoplasm antibody; PH, pulmonary hemorrhage.
Table 4 Trials of induction therapy in AAv in progress or completed and not yet published
Trial Indication (total  
projected n)
Induction (trial) Induction (control) Primary endpoint Trial 
number
Induction trials
MYCYC61 New onset GPA or MPA  
(n=140)
MMF and Pred (n=70) iv Cyc and Pred (n=70) Remission at 6 months NCT00414128
PeXivAS66 Renal MPA or GPA (GFR  
,60 mL per minute) or  
pulmonary hemorrhage 
(n=500)
Plex + standard or  
reduced Pred + Cyc or 
Rtx (n=250)
Plex + standard or reduced 
Pred + Cyc or Rtx (n=250)
Composite of all-cause 
mortality and eSRD
NCT00987389
CLeAR67 Renal GPA or MPA (GFR  
.25mL per minute, n=60)
CCX168 + Cyc + half  
dose or no Pred
Cyc + standard Pred Safety of CCX168  
(secondary  
corticosteroid use)
NCT01363388
SPARROw130 Relapsed GPA (n=216) Gusperimus and Pred Cyc and Pred or rituximab  
and Pred or MTX and Pred
Proportion of patients  
in complete or partial  
remission
NCT01446211
ALeviATe118 Refractory GPA or MPA  
(n=24)
Alemtuzumab 30 mg  
on day 1 and 2 at 0 and 
6 months (high dose)
Alemtuzumab 15 mg on day 
1 and 2 at 0 and 6 months  
(low dose)
Proportion of patients  
in complete or partial  
remission
NCT01405807
Abbreviations: AAv, anti-neutrophil cytoplasm antibody-associated small vessel vasculitides; CCX168, C5a receptor antagonist; eSRD, end-stage renal disease; GFR, 
glomerular filtration rate; IV, intravenous; Plex, plasma exchange; Pred, prednisone or prednisolone; Cyc, cyclophosphamide; MMF, mycophenolate mofetil; MTX, 
methotrexate; Rtx, rituximab; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; MYCYC, A randomized clinical trial of mycophenolate mofetil versus 
cyclophosphamide for remission induction in ANCA-associated vasculitis; PeXivAS; An international Randomized Controlled Clinical Trial Assessing Plasma exchange and 
Steroid Dosing in the Treatment of Severe Anti-Neutrophil Cytoplasm Antibody (ANCA) Associated vasculitis; CLeAR, C5aR inhibitor on Leukocytes exploratory ANCA-
associated Renal vasculitis; SPARROw, SPAnidin in Relapsing gRanulomatosis with pOlyangiitis; ALeviATe, Alemtuzumab for ANCA-Associated Refractory vasculitis; 
ANCA, anti-neutrophil cytoplasm antibody.
pulsed intravenous cyclophosphamide given every 2–3 
weeks for 3–6 months until disease remission was attained 
was as effective in inducing remission as daily oral cyclo-
phosphamide, whilst the total dose of cyclophosphamide 
administered was approximately half in the intravenous 
cyclophosphamide group.57 Longer-term follow-up of 
patients from this study demonstrated a higher relapse rate 
in the intravenous cyclophosphamide group; however, there 
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was no difference in mortality or renal function at the end of 
the study.58 Due to the toxicity of cyclophosphamide, lower-
dose therapy is generally preferred.
Assessing alternatives  
to cyclophosphamide
The NORAM (Nonrenal Wegener’s Granulomatosis Treated 
Alternatively with Methotrexate) study demonstrated that 
methotrexate was as effective as cyclophosphamide in 
inducing remission in early systemic AAV, but in the longer 
term, disease control was less effective in the methotrexate 
arm.59,60 Therefore, methotrexate induction is usually reserved 
for patients with localized or early systemic disease without 
major tissue destruction, although it is used more commonly 
to maintain remission.
Mycophenolate mofetil (MMF) 2–3 g/day has been com-
pared with intravenous cyclophosphamide for induction therapy 
in AAV in MYCYC (A randomized clinical trial of mycophe-
nolate mofetil versus cyclophosphamide for remission induc-
tion in ANCA-associated vasculitis) and presented in abstract 
form.61 The primary endpoint was remission whilst adhering to 
the glucocorticoid regimen, and this occurred in 46/70 of the 
MMF group compared with 48/70 of the intravenous cyclo-
phosphamide group. This study just failed to demonstrate the 
noninferiority for MMF, but the secondary endpoint of remis-
sion irrespective of steroid compliance was achieved. However, 
unpublished data would suggest that the relapse rate was higher 
in the MMF group and further details are awaited.
Targeting B cells with rituximab in combination with 
corticosteroids has proven to be noninferior to cyclophos-
phamide and corticosteroids followed by azathioprine for 
inducing remission in AAV, as demonstrated in the RAVE 
(Rituximab in ANCA-Associated Vasculitis) and  RITUXVAS 
(Rituximab Versus Cyclophosphamide in ANCA-Associated 
Vasculitis) studies.62,63 In the RAVE study, rituximab was 
more effective than cyclophosphamide in achieving remission 
in the subgroup of patients with relapsing disease.62,64 Ritux-
imab is a chimeric monoclonal  antibody binding to CD20, 
an antigen expressed on the surface of B cells, leading to a 
reduction in the numbers of  circulating B cells for a variable 
period of 4–12 months. B cells are the precursors of ANC-
producing plasma cells, and in addition, PR3-specific affinity-
matured B cells were found in nasal biopsy specimens from 
patients with active GPA.65 Rituximab is not known to reduce 
fertility or to promote cancer, so this treatment has provided 
an important  additional option for induction therapy of AAV, 
and may also enable patients with relapsing disease to avoid 
high cumulative doses of cyclophosphamide.
Reducing corticosteroid exposure  
during induction treatment
For systemic GPA, high-dose corticosteroids are used as part 
of the induction regimen, initially at 1 mg/kg up to 60 mg/day. 
These are weaned down over several weeks to a dose of 10 
mg daily after around 3 months or once remission is attained. 
High-dose corticosteroids are associated with a number of 
short-term and long-term side effects (Table 2). Infections 
are the commonest cause of death in the first year after the 
diagnosis of AAV.52 Substitution of rituximab for cyclophos-
phamide failed to reduce the early adverse event rates in the 
RAVE and RITUXVAS trials, including infections.62,63 This 
disappointing result tends to implicate high-dose corticoster-
oids, used as part of the induction regimen, in the infection 
rate. The RAVE and RITUXVAS trials both used intravenous 
 methylprednisolone at induction, which may have contributed 
to the adverse event rate. Minimization of steroid exposure 
is a key target for future trials. PEXIVAS [An International 
Randomized Controlled Clinical Trial Assessing Plasma 
Exchange and Steroid Dosing in the Treatment of Severe 
Anti-Neutrophil Cytoplasm Antibody (ANCA)  Associated 
Vasculitis] is examining the effect of more rapid weaning of 
steroids on the outcomes in patients with AAV.66 The CLEAR 
(C5aR inhibitor on  Leukocytes  Exploratory ANCA-associated 
Renal Vasculitis) study is examining whether a C5a receptor 
antagonist (CCX168) can reduce or eliminate the need for 
oral corticosteroids in induction therapy for AAV.67
Management of severe  
and refractory GPA
Plasma exchange is recommended for patients presenting 
with AAV with severe renal inflammation causing acute 
renal dysfunction. The rationale is for rapid removal of 
ANCA, and possibly other inflammatory mediators, before 
immunomodulatory and anti-inflammatory drugs have had 
an impact.68 The MEPEX (Methylprednisolone versus Plasma 
Exchange) trial was designed to assess renal recovery in 
patients with AAV and serum creatinine .500 μmol/L.69 
Although benefit from plasma exchange in terms of renal 
recovery was achieved, longer-term follow-up demonstrated 
no difference in long-term mortality.70 This uncertainty led to 
the design of the PEXIVAS trial, recruiting a larger number 
of patients (n=500) and including those with pulmonary 
hemorrhage. Hopefully, this study will answer the question 
of whether plasma exchange is indicated in severe renal AAV 
more definitively, and also determine the utility of plasma 
exchange in pulmonary hemorrhage and lesser degrees of 
renal impairment.66
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Approximately 5% of patients with GPA fail to go 
into remission after induction therapy, and are termed 
refractory.71,72 This group of patients is particularly difficult 
to manage. The German Registry of Autoimmune Diseases 
published an analysis of the responses of patients with AAV 
(50/58 with GPA) refractory to rituximab. Forty percent 
were classified as complete responders, and a further 52.7% 
demonstrated a partial response, indicating that rituximab 
should be considered as first-line therapy in patients not 
responding to cyclophosphamide induction.73 Open-label 
studies suggest a number of options for patients not respond-
ing to cyclophosphamide or rituximab, ie, alemtuzumab 
(anti-CD52), tumor necrosis factor (TNF) antagonists, myco-
phenolate mofetil, 15-deoxyspergualin (an antiproliferative 
agent targeting antigen-stimulated B cells), or intravenous 
immunoglobulin.72,74–79 Intravenous immunoglobulin can 
be helpful as an option in patients with active infection or 
those who have not tolerated immunosuppression, although 
frequent retreatment may be required.74,75
Predictive tools to determine 
who can safely stop maintenance 
immunosuppression
Disease relapse remains a problem in GPA, with a 50% 
relapse rate over the course of 5 years.3 Minor relapses may 
be managed with an increase in oral glucocorticoids or 
optimization of maintenance immunosuppression dosing, 
but major relapses require repeated induction therapy. The 
risk of relapse of GPA and PR3-ANCA-positive vasculitis 
is higher than for other forms of vasculitis such as MPA, 
and previous relapse is also predictive of future flares.10,43,64 
Lung and upper airways involvement in GPA are associated 
with higher relapse rates.10 Reduced intensity induction 
therapy42,59 or early withdrawal of immunosuppression or 
 glucocorticoids80 has been associated with an increased risk 
of relapse. However, although risk factors of relapse can be 
defined at a population level, we are unable to predict with any 
great degree of certainty the outcome for any one  particular 
patient with GPA. Therefore, close clinical monitoring of 
symptoms, signs, and inflammatory markers is required to 
detect relapses at an early stage, and it is likely that many 
patients are immunosuppressed for longer than necessary, due 
to uncertainty about their risk of relapse. ANCA positivity is a 
good diagnostic marker for GPA.45 However, a meta-analysis 
of available studies showed that a rise in ANCA titers dur-
ing remission was only weakly associated with relapse, and 
therefore not very useful for predicting the disease course in 
individual patients.44 It is our practice not to modify treatment 
based on changes in ANCA status alone, but to monitor 
patients with rising ANCA titers carefully for clinical signs 
of relapse, along with monitoring inflammatory markers 
such as C-reactive protein. There is a need for more reliable 
biomarkers to predict relapse in AAV patients.
McKinney et al have discovered a CD8 T cell messenger 
RNA signature detectable at diagnosis, which was associated 
with relapse in patients with AAV and a range of autoimmune 
conditions.81 This signature was only discernible in isolated 
leukocyte subsets and not in whole blood. If a clinically appli-
cable test could be devised based on these findings it could 
have some utility in predicting relapse in GPA. Calprotectin 
(S100A8/S100A9) is a damage associated molecular pattern 
produced by neutrophils and monocytes, and is commonly 
raised in inflammatory conditions. In a subset of 27 patients 
with early systemic AAV recruited into the NORAM study, 
levels of calprotectin over 626 ng/mL at one month after 
treatment was initiated were associated with future relapse, 
with a sensitivity of 72.6% and a specificity of 92.3%, and 
similarly higher calprotectin levels at 6 months were also 
significantly associated with relapse.82 Serum calprotectin 
levels are now being prospectively assessed as biomarkers for 
relapse in AAV. Urinary monocyte chemoattractant protein 1 
levels were associated with active renal vasculitis; however, 
it has not yet been determined whether these changes occur 
earlier than other clinical evidence of renal vasculitis, and 
therefore whether they have value in predicting relapse.83
Improving the efficacy of 
maintenance therapy for GPA
Once patients with GPA attain clinical remission, they are 
switched to a less toxic maintenance regimen. However, 
relapse commonly occurs, and some patients will have 
several relapses during their lifetime, leading to accumula-
tion of disease-associated damage and drug-related toxicity. 
A number of clinical trials have compared the safety and 
efficacy of remission maintenance agents in AAV (Table 5), 
and trials that are ongoing are listed in Table 6.
Trials comparing maintenance  
therapies in GPA
The IMPROVE (International Mycophenolate Mofetil 
Protocol to Reduce Outbreaks of Vasculitides) study found 
that MMF was less effective at maintaining remission than 
azathioprine in AAV.84 Therefore, MMF is usually reserved 
for patients who do not tolerate azathioprine. The WEGENT 
(Wegener’s Granulomatosis-Entretien/Maintenance) 
study found no differences in efficacy or safety between 
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Table 5 Completed multicenter randomized controlled trials of remission maintenance therapy in AAv
Maintenance 
trials
Indication Induction Maintenance  
(trial)
Maintenance  
(control)
Primary  
endpoint
Brief results
CYCAZAReM56 Newly diagnosed GPA 
or MPA, with renal or 
multiorgan involvement
Oral Cyc + 
Pred
Aza + Pred  
(n=71)
Oral Cyc + Pred  
(n=73)
Relapse rate No difference in relapse 
rate at 18 months
iMPROve84 Newly diagnosed GPA 
or MPA
Cyc + Pred MMF + Pred  
(n=76)
Aza + Pred  
(n=80)
Relapse-free  
survival
MMF less effective 
than Aza in maintaining 
remission. No difference 
in adverse events
weGeNT85 GPA or MPA with  
renal or multiorgan  
involvement
iv Cyc +  
Pred
Mtx + Pred  
(n=63)
Aza + Pred  
(n=63)
Adverse event  
causing treatment  
cessation or death
No difference in adverse 
events or relapse
wGeT86 GPA and BvAS .3 iv Cyc/oral Mtx 
+ Pred ± etn
Aza or Mtx  
plus etn 
(n=89)
Aza or Mtx  
(n=92)
Remission for  
.6 months
etn failed to improve 
sustained remission rates. 
No difference in adverse 
events. 
German Network 
of Rheumatic  
Diseases study87
GPA and creatinine  
,1.3 mg/dL
Oral Cyc +  
Pred
Lef + pred  
(n=26)
Mtx + pred  
(n=28)
Relapse Lef at 30 mg/day more 
effective than Mtx in 
maintaining remission but 
with more adverse events
Abbreviations: AAv, anti-neutrophil cytoplasm antibody-associated small vessel vasculitides; BvAS, Birmingham vasculitis Activity index; GPA, granulomatosis with 
polyangiitis; MPA, microscopic polyangiitis; Aza, azathioprine; Cyc, cyclophosphamide; Mtx, methotrexate; MMF, mycophenolate mofetil; Pred, prednisolone or prednisone; 
Lef, leflunomide; Etn, etanercept; IV, intravenous; CYCAZAREM, Cyclophosphamide vs azathioprine for early remission phase of vasculitis; IMPROVE, International 
Mycophenolate Mofetil Protocol to Reduce Outbreaks of vasculitides; weGeNT, wegener’s Granulomatosis-entretien/Maintenance; wGeT, wegener’s Granulomatosis 
etanercept Trial.
Table 6 Trials of maintenance therapy in AAv in progress or completed and not yet published
Trial Indication Induction Maintenance  
(trial)
Maintenance 
(control)
Primary endpoint Trial 
number
Maintenance trials
ReMAiN131 GPA or MPA patients who 
remain c-ANCA positive  
in remission (n=180)
Cyc + Pred Aza for 48 months Aza for 18 months Disease-free survival  
during 48 months of  
follow-up
NCT00128895
MAiNRiTSAN90 New or relapsed GPA or  
MPA within a month of  
remission (n=117)
Cyc + Pred Rtx 0.5 mg every  
6 months with last 
dose at month 18
Aza 2 mg/kg tapering 
from 12 months to  
zero at 22 months
Number of major  
relapses (BvAS .10)  
within 28 months
NCT00748644
RiTAZAReM91 Relapsing GPA or MPA  
(n=190)
Rtx + Pred Rtx 1 g every  
4 months for 2 years 
then monitor for  
2 years
Aza for 2 years, then 
monitor for 2 years
Time to first relapse NCT01697267
BRevAS132 ANCA-positive GPA or  
MPA in remission treated  
for active disease in past  
26 weeks (n=400)
Cyc + Pred 
or Rtx +  
Pred
Belimumab plus Aza 
2 mg/kg
Placebo plus Aza  
2 mg/kg
Time to first relapse NCT01663623
Abbreviations: AAv, anti-neutrophil cytoplasm antibody-associated small vessel vasculitides; Cyc, cyclophosphamide; Pred, prednisone or prednisolone; Rtx, rituximab; 
Aza, azathioprine; BvAS, Birmingham vasculitis Activity index; ReMAiN, Randomized trial of prolonged remission-maintenance therapy in systemic vasculitis; MAiNRiTSAN, 
Efficacy Study of Two Treatments in the Remission of Vasculitis; RITAZAREM, Rituximab Vasculitis Maintenance Study; BREVAS, Belimumab in Remission of VASculitis; GPA, 
granulomatosis with polyangiitis; MPA, microscopic polyangiitis; ANCA, anti-neutrophil cytoplasm antibody.
azathioprine and methotrexate for maintenance of remis-
sion, and so they are considered equivalent,85 although 
methotrexate cannot be used in patients with significant 
renal  dysfunction. Etanercept was not effective as an add-on 
maintenance  strategy in AAV.86 Leflunomide is an alternative 
maintenance agent, usually reserved for patients intolerant 
of other agents, given that the clinical trial suggested more 
adverse events than methotrexate.87
Eighteen-month follow-up data from the RAVE 
study demonstrated that patients treated with rituximab 
and corticosteroids alone had the same relapse rate as 
patients treated with cyclophosphamide followed by aza-
thioprine maintenance.64 Patients who achieved remission in 
this study were weaned off oral glucocorticoids. One third 
of patients relapsed during the study, and therefore neither 
regimen was very effective at maintaining remission in this 
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setting. Two cohort studies have demonstrated that in relaps-
ing patients, scheduled maintenance therapy with rituximab 
appears to be an effective option for maintaining remission 
in AAV, although relapses did occur after discontinuation.88,89 
The relative efficacy of azathioprine maintenance compared 
with scheduled rituximab retreatment has been investigated 
in MAINRITSAN (Efficacy Study of Two Treatments in the 
Remission of Vasculitis), a randomized study that has been 
published in abstract form and showing superior disease 
control in patients maintained on rituximab.90 In addition, 
RITAZAREM (the Rituximab Vasculitis Maintenance 
Study),91 comparing rituximab or azathioprine maintenance 
is currently ongoing. The cumulative effects of rituximab 
therapy in AAV are unknown. There have been a few reports 
of John Cunningham (JC) virus infection leading to progres-
sive multifocal leukoencephalopathy following rituximab, 
although these cases have involved patients exposed to 
significant immunosuppression over a period of time.92 
The other long-term complication ascribed to rituximab is 
hypogammaglobulinemia, which again seems to be related 
to cumulative exposure to immunosuppression.93 There is an 
obligation therefore to try to avoid excessive immunosup-
pression, even in patients at risk of relapse, and means to 
better predict relapse are urgently required.
evidence to determine duration  
of maintenance therapy in GPA
The optimal duration of corticosteroid and maintenance 
immunosuppressant treatment in GPA is not known, and in 
reality is likely to vary between individual patients. In one 
retrospective study, withdrawal of corticosteroid treatment 
at 6 months was associated with reduced infections and no 
increase in relapse rate compared with those maintained on 
corticosteroids.94 However, in other studies, early withdrawal 
of steroids has been associated with increased relapse rates.80 
A randomized trial to compare maintenance of patients pre-
senting with PR3-ANCA-positive disease using azathioprine 
for 2 years or 4 years has been reported in abstract form.95 
It was reported that there was no significant improvement in 
relapse-free survival with the extended course of azathioprine 
at 48 months, with relapse rates of 52%–74% in the differ-
ent groups. It is likely that remission maintenance strategies 
will evolve significantly once the results of current trials are 
available.
Management of localized GPA
For localized disease, a multidisciplinary approach with close 
communication between otolaryngologists, ophthalmologists, 
and physicians is required. Systemic immunosuppression 
combined with local therapy is often necessary. There is evi-
dence of the efficacy of cotrimoxazole in preventing relapse 
of upper respiratory tract GPA, possibly due to the elimination 
of nasal carriage of Staphylococcus aureus.96,97 Localized 
disease can sometimes be treated with methotrexate, but it is 
our practice to reserve this treatment for manifestations where 
the risk of long-term damage is low, based on the results of 
the NORAM study.60 There have been reports that rituximab 
is less effective in treating granulomatous upper airways 
manifestations of GPA than generalized disease,98 but this 
finding has not been confirmed in all studies.99,100 The time 
course of response for granulomatous disease differs from 
vasculitic manifestations, with a more delayed response, 
and this may have affected the assessment of response to 
rituximab in studies with less than 6 months of follow-up. 
Obstructive tracheobronchial disease can be poorly respon-
sive to systemic therapy, and if not effectively treated, can lead 
to permanent tracheal scarring with respiratory compromise 
and increased susceptibility to chest infections. In addition 
to systemic treatment, active tracheobronchial disease can be 
treated locally with intralesional steroids and endoluminal 
surgery with intralesional laser and dilatation.101–103 Tracheal 
endoscopy can be used to monitor treatment response. Nasal 
and sinus disease can be managed locally with intranasal 
corticosteroids, and regular saline douching of nasal crusts. 
Middle ear obstruction may require insertion of grommets. 
Reconstructive surgery for nasal bridge collapse is an option, 
but is only recommended in the absence of active nasal 
vasculitis.
Management of damage and disease/
treatment-associated comorbidity
Compared with age-matched and sex-matched controls in the 
general population, a study of 535 patients with AAV enrolled 
into four EUVAS trials showed a mortality rate of 2.6.8 Forty-
four percent of the deaths during the 5-year follow-up of this 
study occurred within the first year after induction therapy, 
and the main causes of death in the first year were infection 
(48%) and active vasculitis (19%).8 It is not currently clear 
which component of induction therapy contributes most to 
the risk of infection. Half of the infections occurring in the 
first year were observed during the first 2 months of induc-
tion treatment, and unspecified septicemia and bacterial 
infections of the respiratory tract accounted for half of the 
cases.52 Cumulative adverse events during induction therapy 
are significantly associated with  mortality.52 Elderly patients 
and those with severe renal impairment are particularly 
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susceptible to treatment- associated complications.55,104 
Cotrimoxazole is routinely given to patients receiving cyclo-
phosphamide as prophylaxis against Pneumocystis jirovecii 
pneumonia.105
After the first year, the major causes of death in the 
EUVAS cohorts were cardiovascular disease (26%), malig-
nancy (22%), and infection (20%).8 Long-term follow-up 
data from these trials after 7.3 years of follow-up showed 
a significant burden of morbidity, with 34.4% of patients 
having more than five items of damage on the Vasculitis 
Damage Index at long-term follow-up.48 In patients with 
GPA, the commonest items of damage were nasal block-
age/crusting (44.3%), hypertension (39.5%),  hearing loss 
(32.3%), and a glomerular filtration rate ,50 mL per minute 
(31.7%). Impaired pulmonary function (13.8%) and periph-
eral neuropathy (22.2%) were also prominent features. 
Cardiovascular endpoints of angina/coronary artery bypass, 
stroke, and myocardial infarction were also significantly 
increased.48,106 In view of this, attention must be drawn to 
management of cardiovascular risk factors, including smok-
ing, exercise, hypertension, weight management, lipids, and 
management of diabetes, where present. End-stage renal 
disease occurs in up to 25% of patients with AAV.8 Dialysis 
and renal transplantation are options for these patients, and 
patients with AAV have good outcomes of transplantation 
when it is performed after disease activity is controlled.107 
More difficult to manage is permanent lung scarring due 
to pulmonary fibrosis and respiratory compromise due to 
tracheal and bronchial stenosis, which can also predispose 
to recurrent chest infections.
Damage in GPA is not only related to the disease itself, 
but also to treatment. Short-term and long-term toxicities 
associated with treatments commonly used for GPA are 
listed in Table 2. In the EUVAS trials, potential treatment-
related damage items were reported for two thirds of patients. 
Cohorts of GPA patients exposed to high cumulative doses 
of cyclophosphamide have been shown to be at an increased 
risk of bladder malignancy (standardized incidence ratio 
[SIR] 3.6–4.8),49–51 acute myeloid leukemia,50 (SIR 19.6), and 
nonmelanoma skin cancer (SIR 4.7).50 The risk is known to be 
dose-dependent, and increase substantially with cumulative 
doses of cyclophosphamide over 25 g,49,50 but a safe thresh-
old dose for cyclophosphamide has not been  established. 
 However, the risks of bladder malignancy, leukemia, and non-
melanoma skin cancer in the recent EUVAS trials were lower 
than in previous cohorts (SIR 2.4, 3.2, and 2.8,  respectively), 
probably due to reduced cyclophosphamide exposure.47 Aza-
thioprine has been associated with nonmelanoma skin cancer 
in other conditions;108,109 however, in AAV, it is rarely used 
alone and so its contribution to skin cancer in GPA is difficult 
to quantify.  Recommendations for treatment of AAV, includ-
ing prophylaxis for the prevention of treatment-associated 
complications have been produced.105,110
Management of GPA in the future
There is an ongoing need to reduce the toxicity of treat-
ment for GPA, and to increase the efficacy of maintenance 
therapy in preventing relapse. Currently, a means to restore 
immunological tolerance to ANCA autoantigens in AAV 
does not exist. However, the development of biological 
therapeutics and small molecules targeting specific cell types, 
cytokines, and immunological pathways has enabled more 
rational drug targeting in inflammatory diseases. A number 
of new therapeutics targeting immunological pathways have 
a rationale for efficacy in AAV, and these are discussed 
below and shown in Figure 1. Most have yet to be formally 
evaluated for this indication. Clinical trials of emerging 
therapeutics for AAV that are currently ongoing are listed 
in Tables 4 and 6.
B cells
Rituximab, a chimeric human/mouse anti-CD20 B cell-de-
pleting agent, has proven efficacy as induction therapy in AAV 
and is being evaluated for maintenance of remission.62,63,91 
Fully humanized CD20 monoclonal antibodies have been 
developed, including ofatumumab, ocrelizumab, and 
 veltuzumab. Ofatumumab has been licensed for treatment of 
resistant chronic lymphocytic leukemia.111 These agents are 
not currently licensed for treatment of AAV, but they have 
been used “off label” in patients who have allergic reactions 
to rituximab.
B cell activating factor (BlyS) is a cytokine involved in 
the proliferation and maturation of B cells. ANCA-stimulated 
neutrophils release BlyS, and BlyS levels have been shown 
to be elevated in patients with GPA.112–114 Belimumab is a 
fully humanized monoclonal antibody to soluble BlyS, which 
is currently being evaluated in Phase II studies as a relapse 
prevention agent in AAV (Table 6).
Epratuzumab is an anti-CD22 monoclonal antibody 
expressed on follicular B cells in germinal centers. CD22 
is a transmembrane sialoglycoprotein involved in nega-
tive  regulation of signaling via the B cell receptor, and is 
also involved in B cell migration.115 This agent has not yet 
been evaluated for AAV indications, but is being inves-
tigated in a Phase III study for nonrenal systemic lupus 
erythematosus.116
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T cells
T effector memory cells are present in chronic vascu-
litic lesions in patients with GPA,24,25 and T cell help is 
also required for generation of ANCA. Targeting T cell 
costimulation with CTLA4-Ig, abatacept, showed prom-
ising results in a small open-label study.117 Lymphocyte 
depletion with anti-CD52 (Campath-1H®) caused reduc-
tions in circulating lymphocytes, including CD4 T cells 
and was used in a small study in refractory AAV (total 
dose 134 mg).76 Whilst effective in these difficult-to-treat 
patients, the infection rate was high, and so now a second 
study is ongoing using lower doses of Campath-1H (30 
mg or 60 mg) in 24 patients with refractory AAV.118 Raised 
serum levels of IL-23 and IL-17 and antigen-specific 
Th17 cells have been demonstrated in AAV,26 implicating 
the Th17 pathway in pathogenesis. Agents targeting the 
Th17 axis  (inhibitors of IL-17, IL-17 receptor, and IL-12/
IL-23) are under  development, in particular for resistant 
psoriasis,119–121 but these agents have not been evaluated 
for safety or efficacy in AAV.
Complement
Raised levels of alternative pathway complement breakdown 
products have been detected in the serum of patients with active 
AAV and in kidney biopsy specimens.31,32 There is also evi-
dence of the importance of the alternative pathway of comple-
ment in a mouse model of MPO-positive  vasculitis.33 C5a is a 
potent neutrophil chemoattractant, and C5a receptor signaling 
increases the expression of activatory Fc gamma receptors on 
neutrophils.122 These data make C5a and its receptor a poten-
tial anti-inflammatory target in AAV. The CLEAR study is 
evaluating an orally bioavailable C5a receptor antagonist as a 
steroid-sparing agent in induction therapy in AAV.67
Cytokines and small molecule signaling 
inhibitors
TNF-α primes neutrophil responses to ANCA, and increases 
the expression of PR3 on the neutrophil surface.15 In small 
studies, blockade of TNF-α by monoclonal antibodies has 
appeared to be effective in having a steroid-sparing effect 
in AAV.78,123 However, the TNF receptor blocker etanercept 
Autoimmune responses 
Effector responses Neutrophil
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*Rituximab, Ofatumumab,
Ocrelizumab, Veltuzumab
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CCX168
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SYK inhibitor
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Figure 1 A selection of biologics and small molecule inhibitors targeting the autoimmune response and effector responses that may be important in GPA.
Note: *Of these agents, only rituximab is currently licensed for the treatment of GPA, but some of the others are currently undergoing clinical trial evaluation.
Abbreviations: ANCA, anti-neutrophil cytoplasm antibody; GPA, granulomatosis with polyangiitis; iL, interleukin; CCX168, C5a receptor antagonist; BlyS, B cell activating 
factor; TNF, tumor necrosis factor; CD, cluster of differentiation; ANCA, Anti-neutrophil cytoplasm antibody; SYK, spleen tyrosine kinase. 
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failed to show benefit in a larger study.86 Anti-TNF antibod-
ies block both soluble and membrane-bound TNF-α, whilst 
etanercept blocks only the effects of soluble TNF-α, and this 
might account for the differing results. However, due to the 
results with etanercept, TNF-α blockade has not subsequently 
been evaluated in AAV in a large clinical trial. Blockade of 
the IL-6 and IL-1β pathways are other potential anti-inflam-
matory targets that have not yet been evaluated in AAV.
Spleen tyrosine kinase (SYK) is a nonreceptor tyrosine 
kinase that transmits intracellular signals for the B cell receptor 
and activatory Fc gamma receptors, amongst other immunore-
ceptors. SYK inhibitors not only target antibody production, 
but also downstream effector  mechanisms.  Fostamatinib, an 
orally bioavailable inhibitor of SYK, has been found to be 
highly effective in rat experimental  autoimmune glomerulone-
phritis and nephrotoxic nephritis.124,125 Fostamatinib has been 
shown to have efficacy in rheumatoid arthritis in a Phase II 
study,126 but has not been evaluated in AAV.
Conclusion
Management of GPA requires a multidisciplinary approach, 
aiming not only to treat the disease and prevent relapse, 
but also to manage long-term cardiovascular risk, organ 
damage, and side effects of therapy. Treatments have 
been refined as a result of large multicenter randomized 
controlled trials in AAV; however, there are unmet needs 
to resolve granulomatous inflammation more rapidly, to 
reduce steroid exposure, and to improve the efficacy of 
remission maintenance strategies in GPA. There are a large 
number of potentially promising agents for the treatment of 
AAV in development, and clinical trials will be required to 
determine whether these can meet unmet needs for patients 
with GPA.
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